Evidence map›Paper›PMID 39438020›Full record

ArticleAddiction (Abingdon, England)2025

Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011-2020: A national retrospective cohort study.

Rosalyn Fraser, Alan Yeung, Megan Glancy, Matthew Hickman, Hayley E Jones, Saket Priyadarshi, Kirsten Horsburgh, Sharon J Hutchinson, Andrew McAuley

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rosalyn FraserSchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.ORCID 0000-0001-7979-463X
Alan YeungSchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.ORCID 0000-0001-5226-3695
Megan GlancySchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.
Matthew HickmanBristol Medical School, University of Bristol, Tyndall Avenue, Bristol, UK.ORCID 0000-0001-9864-459X
Hayley E JonesBristol Medical School, University of Bristol, Tyndall Avenue, Bristol, UK.ORCID 0000-0002-4265-2854
Saket PriyadarshiSchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.
Kirsten HorsburghScottish Drugs Forum, Glasgow, UK.
Sharon J HutchinsonSchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.
Andrew McAuleySchool of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.ORCID 0000-0002-6047-2400

Funding

TRANSFORM - Transforming the evidence base on estimating prevalence of opioid use disorder and expanded access to interventions to prevent drug related deaths: an international data linkage studyR01DA059822 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI Joshua Adam Barocas, Louisa Degenhardt · 2024 to 2026
$2.3M
HPRU BSENIDA NIH HHS R01 DA059822NIHRPHSProgramme Grants for Applied Research Programme RP-PG-0616-20008Scottish Government Drug Death Task Force
6 · The paper itself

Abstract

BACKGROUND AND

aimsOpioid dependence is associated with an increased risk of suicide. Drug-related mortality among people with opioid dependence in Scotland has more than tripled since 2010; less is known about changes in suicide risk. We aimed to determine if opioid agonist therapy (OAT) in Scotland is protective against suicide and to measure trends in suicide rates in those with opioid dependence over time.

designRetrospective cohort study.

settingScotland, UK.

participants46 453 individuals in Scotland who received at least one prescription for OAT between 2011 and 2020 with over 304 000 person-years (pys) of follow-up. MEASUREMENTS: We calculated standardised mortality ratios (SMR) using the age- and sex-specific suicide rates in Scotland for years 2011-2020. We fitted multivariable competing-risk regression models to estimate suicide rates by OAT exposure and to estimate trends over time, adjusting for potential confounders.

findingsThere were 575 deaths classed as suicide among the cohort and the overall suicide rate was 1.89 (95% confidence interval [CI] = 1.74-2.05) per 1000 pys. Age and sex SMR for suicide was 7.05 times (95% CI = 6.50-7.65) higher than in the general population. After adjustment, OAT was shown to be highly protective against suicide, with rates more than three times greater (adjusted hazard ratio: 3.07; 95% CI = 2.60-3.62) off OAT compared with on OAT. Suicide rates decreased over time, falling from 2.57 (95% CI = 2.19-3.02) per 1000 pys in 2011-12 to 1.48 (95% CI = 1.21-1.82) in 2019-20.

conclusionPeople with opioid dependence in Scotland appear to have a greater risk of suicide than the general population. Treatment is protective, with rates of suicide lower among those on opioid agonist therapy. Suicide rates have decreased over time, during a period in which drug-related death rates in Scotland have risen to globally high levels.

Indexed as

Analgesics, OpioidOpioid-Related DisordersSuicideAdolescentAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedOpiate Substitution TreatmentRetrospective StudiesScotlandYoung AdultAnalgesics, Opioiddemographyepidemiologyinjectingmodellingopiatesopioid agonist treatmentScotlandsuicide

Identifiers

PMID39438020
PMCPMC11707309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.